addiction

Substance abuse treatment center bed

First Opinion

Mental health and addiction care are poorly covered by insurance networks

By Patrick J. Kennedy

TUFTS - Sackler school hats

Health

Tufts will scour Sackler name from its medical campus, in rebuff of family that controls Purdue Pharma

By Andrew Joseph

advertisement

OC Phases

Exclusive

The history of OxyContin, told through unsealed Purdue documents

By Shraddha Chakradhar and Casey Ross

advertisement

Purdue docs

Exclusive

Purdue’s Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared ‘like a tiger,’ files show

Aerial view Huntington, West Virginia

First Opinion

The view from West Virginia: the end of HIV transmission is a distant dream

By Judith Feinberg

Buprenorphine as Methadone Alternative

First Opinion

Changing emergency doctors’ behaviors to promote wider use of medication for opioid use disorder

By Alister Martin and Ted Robertson

Oxy with newsprint

Pharma

How Purdue planted its ‘anti-story’ and delayed the reckoning for its role in the opioid epidemic

By David Armstrong — ProPublica

advertisement

Paul Tonko

Politics

A new bill would let more doctors prescribe addiction treatments without waiting for insurers’ permission

advertisement

Off the Charts

Off the Charts

When it comes to health care, nothing is nonpartisan. Melania Trump’s visit to a Boston hospital harms patients and providers

By Jennifer Adaeze Okwerekwu

Opioid pills

Health

With a new guide to tapering opioids, federal health officials seek a balanced approach to prescribing

By Andrew Joseph

Sesame Street addiction 02

Health

‘Sesame Street’ launches new initiative to help explain parental addiction to kids

By Shraddha Chakradhar

Booneville, Kentucky

First Opinion

Beyond the Sacklers: Free-trade policies contributed to the opioid epidemic

By Adam Dean and Simeon Kimmel

Purdue Pharma headquarters

Business

Purdue Pharma filed for bankruptcy. What does it mean for lawsuits against the opioid manufacturer?

By Andrew Joseph

Purdue Pharma headquarters

Business

Purdue Pharma, maker of OxyContin and other drugs, files for bankruptcy

By Andrew Joseph

TOBACCO TRIAL

Pharma

Historians push to create public archive of documents from massive opioid litigation

By Andrew Joseph

PHILLIP MORRIS HEADQUARTERS

First Opinion

Don’t let the opioid settlement fritter away funds like the tobacco settlement did

By Kathleen T. Brady

Purdue Pharma headquarters

Pharma

OxyContin maker Purdue Pharma agrees to tentative settlement in opioid lawsuits

By Associated Press

Purdue headquarters in shadow

Health

Purdue Pharma touts data that downplay its role in the opioid epidemic, new analysis shows

By David Armstrong and Jeff Ernsthausen — ProPublica

National Overdose Awareness Day

First Opinion

Removing the stigma of opioid addiction is a corporate responsibility

By Kate Cronin

Demonizing pain meds

First Opinion

Who is really behind a proposed new definition of pain?

By Dawn Rae Downton

Emergency room bays

First Opinion

Every hospital needs ‘recovery coaches’ for patients with substance use problems

By James Baird

The Readout LOUD

Listen: Purdue, J&J, and a week of big opioid crisis news

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

OxyContin

Health

Purdue Pharma, government attorneys in settlement talks

By Associated Press

Pharma

Watch: In never-before-seen video, Purdue’s Richard Sackler defends OxyContin marketing

By David Armstrong — ProPublica

Opioid Lawsuit Oklahoma

Health

Oklahoma judge finds Johnson & Johnson fueled opioid crisis

By Associated Press

STAT Purdue illustration

First Opinion

Lost lives and long odds: Inside STAT’s decision to take on Purdue

purdue collage

Pharma

STAT wins long legal fight as Kentucky Supreme Court clears way for release of Purdue OxyContin files

By Andrew Joseph and Casey Ross

Alex Azar - July 2019

Politics

In bid to improve care, Trump administration to relax privacy rules for patients with history of addiction

Methadone clinic

Health

For the first time, U.S. panel recommends screening adults for illicit drug use

By Brittany Flaherty